Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma

Bjoern G. Volkmer, Evelyn M. Seidl-Schlick, D. Bach, I. Romics, Klaus Kleinschmidt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract. The aim of this study was to evaluate the long-term impact of cyclophosphamide on patients with a history of superficial bladder cancer. Between July 1986 and January 1988, 58 consecutive patients with primary superficial transitional cell carcinoma of the bladder were included in this study. All patients had a transurethral R0 resection. Then 6 weekly intravesical instillations of 120 mg bacillus Calmette-Guérin (BCG) were performed. Until June 1987, 22 consecutive patients (group A) received an additional intravenous application of 700 mg/m2 cyclophosphamide prior to the BCG immunotherapy, while from July 1987 36 patients were treated without cyclophosphamide. Survival was calculated using the Kaplan-Meier method and comparison of survival using the log rank test. Tumor staging, grading, and size were equally distributed in both groups. No significant difference could be observed regarding the 10-year overall survival rate (group A: 59%, group B: 58%), the 10-year tumor-specific survival rate (89 vs 94%), and the 10-year progression-free survival rate (85 vs 97%). There was a statistically significant deterioration of the 10-year recurrence-free survival rate in the cyclophosphamide group (44 vs 70%, log rank test: p

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalClinical Rheumatology
Volume24
Issue number4
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Transitional Cell Carcinoma
Cyclophosphamide
Survival Rate
Bacillus
Urologic Neoplasms
Intravesical Administration
Survival
Neoplasm Grading
Neoplasm Staging
Urinary Bladder Neoplasms
Immunotherapy
Disease-Free Survival
Urinary Bladder
Recurrence
Incidence
Neoplasms

Keywords

  • Bacillus Calmette-Guérin
  • Cyclophosphamide
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. / Volkmer, Bjoern G.; Seidl-Schlick, Evelyn M.; Bach, D.; Romics, I.; Kleinschmidt, Klaus.

In: Clinical Rheumatology, Vol. 24, No. 4, 08.2005, p. 319-323.

Research output: Contribution to journalArticle

Volkmer, Bjoern G. ; Seidl-Schlick, Evelyn M. ; Bach, D. ; Romics, I. ; Kleinschmidt, Klaus. / Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. In: Clinical Rheumatology. 2005 ; Vol. 24, No. 4. pp. 319-323.
@article{aa02d07719474390a79bdead67905ee0,
title = "Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma",
abstract = "Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract. The aim of this study was to evaluate the long-term impact of cyclophosphamide on patients with a history of superficial bladder cancer. Between July 1986 and January 1988, 58 consecutive patients with primary superficial transitional cell carcinoma of the bladder were included in this study. All patients had a transurethral R0 resection. Then 6 weekly intravesical instillations of 120 mg bacillus Calmette-Gu{\'e}rin (BCG) were performed. Until June 1987, 22 consecutive patients (group A) received an additional intravenous application of 700 mg/m2 cyclophosphamide prior to the BCG immunotherapy, while from July 1987 36 patients were treated without cyclophosphamide. Survival was calculated using the Kaplan-Meier method and comparison of survival using the log rank test. Tumor staging, grading, and size were equally distributed in both groups. No significant difference could be observed regarding the 10-year overall survival rate (group A: 59{\%}, group B: 58{\%}), the 10-year tumor-specific survival rate (89 vs 94{\%}), and the 10-year progression-free survival rate (85 vs 97{\%}). There was a statistically significant deterioration of the 10-year recurrence-free survival rate in the cyclophosphamide group (44 vs 70{\%}, log rank test: p",
keywords = "Bacillus Calmette-Gu{\'e}rin, Cyclophosphamide, Transitional cell carcinoma",
author = "Volkmer, {Bjoern G.} and Seidl-Schlick, {Evelyn M.} and D. Bach and I. Romics and Klaus Kleinschmidt",
year = "2005",
month = "8",
doi = "10.1007/s10067-004-1032-2",
language = "English",
volume = "24",
pages = "319--323",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "4",

}

TY - JOUR

T1 - Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma

AU - Volkmer, Bjoern G.

AU - Seidl-Schlick, Evelyn M.

AU - Bach, D.

AU - Romics, I.

AU - Kleinschmidt, Klaus

PY - 2005/8

Y1 - 2005/8

N2 - Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract. The aim of this study was to evaluate the long-term impact of cyclophosphamide on patients with a history of superficial bladder cancer. Between July 1986 and January 1988, 58 consecutive patients with primary superficial transitional cell carcinoma of the bladder were included in this study. All patients had a transurethral R0 resection. Then 6 weekly intravesical instillations of 120 mg bacillus Calmette-Guérin (BCG) were performed. Until June 1987, 22 consecutive patients (group A) received an additional intravenous application of 700 mg/m2 cyclophosphamide prior to the BCG immunotherapy, while from July 1987 36 patients were treated without cyclophosphamide. Survival was calculated using the Kaplan-Meier method and comparison of survival using the log rank test. Tumor staging, grading, and size were equally distributed in both groups. No significant difference could be observed regarding the 10-year overall survival rate (group A: 59%, group B: 58%), the 10-year tumor-specific survival rate (89 vs 94%), and the 10-year progression-free survival rate (85 vs 97%). There was a statistically significant deterioration of the 10-year recurrence-free survival rate in the cyclophosphamide group (44 vs 70%, log rank test: p

AB - Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract. The aim of this study was to evaluate the long-term impact of cyclophosphamide on patients with a history of superficial bladder cancer. Between July 1986 and January 1988, 58 consecutive patients with primary superficial transitional cell carcinoma of the bladder were included in this study. All patients had a transurethral R0 resection. Then 6 weekly intravesical instillations of 120 mg bacillus Calmette-Guérin (BCG) were performed. Until June 1987, 22 consecutive patients (group A) received an additional intravenous application of 700 mg/m2 cyclophosphamide prior to the BCG immunotherapy, while from July 1987 36 patients were treated without cyclophosphamide. Survival was calculated using the Kaplan-Meier method and comparison of survival using the log rank test. Tumor staging, grading, and size were equally distributed in both groups. No significant difference could be observed regarding the 10-year overall survival rate (group A: 59%, group B: 58%), the 10-year tumor-specific survival rate (89 vs 94%), and the 10-year progression-free survival rate (85 vs 97%). There was a statistically significant deterioration of the 10-year recurrence-free survival rate in the cyclophosphamide group (44 vs 70%, log rank test: p

KW - Bacillus Calmette-Guérin

KW - Cyclophosphamide

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=23344446899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344446899&partnerID=8YFLogxK

U2 - 10.1007/s10067-004-1032-2

DO - 10.1007/s10067-004-1032-2

M3 - Article

C2 - 16034647

AN - SCOPUS:23344446899

VL - 24

SP - 319

EP - 323

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 4

ER -